Survival Outcomes Associated with First and Second-Line Palliative Systemic Therapies in Patients with Metastatic Bladder Cancer
CONCLUSION: real-world mOS of >1.5 years in mBC is unprecedented and supports using multiple lines of PST. Furthermore, immunotherapy may be a comparable alternative to chemotherapy in both 1L and 2L settings.PMID:34677243 | PMC:PMC8534510 | DOI:10.3390/curroncol28050325
Source: Current Oncology - Category: Cancer & Oncology Authors: Arshia Beigi Saba Vafaei-Nodeh Longlong Huang Shaun Z Sun Jenny J Ko Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Palliative | Study